The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).

被引：8

作者：

Tsuji, Akihito

Ohori, Hisatsugu

Yamaguchi, Tatsuro

Matsuura, Masato

Nishioka, Atsujiro

Makiyama, Akitaka

Noura, Shingo

Kochi, Mitsugu

Sagawa, Tamotsu

Kotaka, Masahito

Kubota, Yutaro

Sunakawa, Yu

Sekikawa, Takashi

Nakamura, Masato

Takeuchi, Masahiro

Ichikawa, Wataru

Fujii, Masashi

机构：

[1] Kagawa Univ Hosp, Dept Med Oncol, Takamatsu, Kagawa, Japan

[2] Japanese Red Cross Ishinomaki Hosp, Dept Med Oncol, Ishinomaki, Japan

[3] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Surg, Tokyo, Japan

[4] Kobe City Nishi Kobe Med Ctr, Dept Surg, Kobe, Hyogo, Japan

[5] Saga Univ Hosp, Div Hematol Resp Med & Oncol, Saga, Japan

[6] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan

[7] Toyonaka City Hosp, Dept Surg, Toyonaka, Osaka, Japan

[8] Nihon Univ, Itabashi Hosp, Dept Digest Surg, Tokyo, Japan

[9] Natl Hosp Org Hokkaido Canc Ctr, Div Gastroenterol, Sapporo, Hokkaido, Japan

[10] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Hyogo, Japan

[11] Showa Univ Hosp, Div Med Oncol, Tokyo, Japan

[12] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Kanagawa, Japan

[13] Showa Univ, Fujigaoka Hosp, Div Clin Oncol, Dept Internal Med, Yokohama, Kanagawa, Japan

[14] Aizawa Hosp, Aizawa Comprehens Canc Ctr, Matsumoto, Nagano, Japan

[15] Kitasato Univ, Sch Pharm, Dept Clin Med Biostat, Tokyo, Japan

[16] Showa Univ, Fujigaoka Hosp, Div Med Oncol, Yokohama, Kanagawa, Japan

[17] Nihon Univ, Sch Med, Dept Digest Surg, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.3501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3501

引用

页数：2